 Indianapolis-based drugmaker says a once-monthly intravenous infusion for adults with early symptoms of Alzheimer's disease, including people with mild cognitive impairment, has shown promise. Kisunla is the drug's marketing name, and it helps remove the buildup of amyloid plaques.